Elias Karam: The ultimate dilemma of corticosteroids and Immunotherapy

Elias Karam, Hematology and Medical Oncology Fellow at Gustave Roussy, shared a post on LinkedIn about a recent paper by Rik J. Verheijden et al. titled “Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials” published in Journal of Clinical Oncology.

Authors: Rik J. Verheijden, Jolien S. de Groot, Babs O. Fabriek, Miki N. Hew, Anne M. May and Karijn P.M. Suijkerbuijk.

“The ultimate dilemma of corticosteroids and Immunotherapy…

Large analysis of 6 clinical trials.

Take away messages:

• Higher corticosteroid peak dose is associated with worse survival across tumor types, while cumulative dose is not.
• Start with lower corticosteroid dose whenever feasible and try not to peak very high.”

Source: Elias Karam/LinkedIn